New asthma injection shows promise in early trial

NCT ID NCT06911866

Completed Disease control Sponsor: Nanjing RegeneCore Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called RC1416 in 40 adults with moderate to severe asthma. Participants received a single injection of either the drug or a placebo. The main goal was to check safety and how the body processes the drug, with a preliminary look at whether it helps control asthma. Results will guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RC1416 injection
What this could lead to: If successful, this could point toward a new treatment option for people with moderate to severe asthma that is not well controlled by current therapies.
What could go wrong: This is an early Phase 1b study with only 40 participants, focused mainly on safety and dosing. It is too small and early to know if RC1416 will actually improve asthma symptoms or be better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE ASTHMA

Contacts and locations

Locations

China-Japan Friendship Hospital

Beijing, Beijing Municipality, 100029, China
Hangzhou First People's Hospital

Hangzhou, Zhejiang, China
Hebei Petro China Centre Hospital

Langfang, Hebei, China
Hebei Province Hospital of Chinese Medicine

Shijiazhuang, Hebei, China
Jining NO.1 people's hospital

Jining, Shandong, China
Liaocheng People's Hospital

Liaocheng, Shandong, China
Nanjing First Hospital

Nanjing, Jiangsu, China
Nanyang Central Hospital

Nanyang, Henan, China
Peking University Shougang Hospital

Beijing, Beijing Municipality, China
Shanxi Bethune Hospital

Taiyuan, Shanxi, China
Shenzhen People's Hospital

Shenzhen, Guangdong, China
The First Affiliated Hospital of Baotou Medical College

Baotou, Inner Mongolia, China
The First Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China
The Second Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China
Xinxiang First People's Hospital

Xinxiang, Henan, China
Zibo Municipal Hospital

Zibo, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.